Pyridoxine in Preventing Hand-Foot Syndrome Caused by Capecitabine in Patients With Cancer

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial

Official title:

Randomized Double-Blind Placebo-Controlled Trial of Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome (HFS)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00486213
• Other study ID #: CDR0000551757
• Secondary ID: SINGAPORE-06-22-
• Status: Terminated
• Phase: Phase 3
• First received: June 13, 2007
• Last updated: September 22, 2015
• Start date: June 2007
• Est. completion date: August 2014

Study information

• Verified date: September 2015
• Source: National Cancer Centre, Singapore
• Contact: n/a
• Is FDA regulated: No
• Health authority: Singapore: Health Sciences Authority
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Pyridoxine may help prevent hand-foot syndrome caused by capecitabine in patients with cancer. It is not yet known whether pyridoxine is more effective than a placebo in preventing hand-foot syndrome in patients with cancer.

PURPOSE: This randomized phase III trial is studying pyridoxine to see how well it works compared with a placebo in preventing hand-foot syndrome caused by capecitabine in patients with cancer.

Description:

OBJECTIVES:

Primary

• Compare the incidence of capecitabine-induced palmar-plantar erythrodysesthesia (hand-foot syndrome [HFS]) ≥ grade 2 in patients with cancer treated with pyridoxine hydrochloride vs placebo.

Secondary

• Compare the time to onset of HFS ≥ grade 2 in patients treated with these regimens.

• Compare the quality of life changes in patients treated with these regimens.

• Identify factors predicting toxicity from capecitabine chemotherapy.

OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are stratified according to gender and treatment setting (adjuvant/neoadjuvant vs palliative setting). Patients are randomized to 1 of 2 treatment arms.

• Arm I: Beginning concurrently with planned capecitabine treatment, patients receive oral pyridoxine hydrochloride once daily on days 1-21.

• Arm II: Beginning concurrently with planned capecitabine treatment, patients receive oral placebo once daily on days 1-21.

In both arms, treatment repeats every 21 days for up to 8 courses (until discontinuation of capecitabine treatment).

Quality of life is assessed at baseline, at the beginning of courses 2, 4, 6, and 8, and at the end of the study.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 210
• Est. completion date: August 2014
• Est. primary completion date: August 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

DISEASE CHARACTERISTICS:

• Diagnosis of cancer

• Must be receiving single-agent capecitabine either in the adjuvant/neoadjuvant or palliative setting at a dose of = 1000 mg/m² twice daily on days 1-14 (given in 3-week courses)

PATIENT CHARACTERISTICS:

• Life expectancy > 12 weeks

• No preexisting neuropathy

• No known allergy to pyridoxine hydrochloride and its incipients

• No other dermatologic condition that, in the opinion of the physician, may affect the hands or feet or may complicate evaluation during study treatment

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• No prior capecitabine

• Concurrent radiotherapy, steroids, and/or biological therapy (e.g., trastuzumab [Herceptin®] or bevacizumab) allowed provided they do not cause hand-foot syndrome (HFS)

• No other concurrent drugs (e.g., docetaxel or doxorubicin hydrochloride liposome) that can cause HFS

• No concurrent drugs (e.g., oxaliplatin or taxanes) that can cause neuropathy

• No concurrent pyridoxine hydrochloride-containing preparations (e.g., multivitamins or vitamin B complex)

• No concurrent over-the-counter products that contain urea or lactic acid

• No concurrent drugs reported to have drug interactions with pyridoxine hydrochloride (e.g., cycloserine; hydralazine; immunosuppressants; isoniazid; levodopa; estrogen or estrogen-containing contraceptives; penicillamine; phenobarbitone; phenytoin; or pyrazinamide)

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Dermatologic Complications
• Hand-Foot Syndrome
• Palmar-plantar Erythrodysesthesia
• Unspecified Adult Solid Tumor, Protocol Specific

Intervention

Dietary Supplement:
• pyridoxine hydrochloride
Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle

Other:
• Placebo

Locations

Country	Name	City	State
Singapore	National Cancer Centre - Singapore	Singapore

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Centre, Singapore

Country where clinical trial is conducted

Singapore, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	First incidence of hand-foot syndrome (HFS) = grade 2 according to NCI CTCAE vs 3.0		up to 8 cycles	No
Secondary	Time to the onset of HFS = grade 2		days to weeks	No
Secondary	Quality of life as measured by EuroQOL (EQ-5D) questionnaire		QOL assessment at baseline, at beginning of cycles 2, 4, 6, 8 and at the end of the study.	No